Cognitact Graces the 9th China Biomed Innovation and Investment Conference

The 9th China Biomed Innovation and Investment Conference (CBIIC 2024), a flagship event jointly organized by the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Hong Kong Exchanges and Clearing Limited (HKEX), and iMeta (Beijing) Health Information Consulting Co ., Ltd., was grandly held at the Guangzhou Baiyun International Convention Center from November 30 to December 1, 2024. Cognitact Ltd., a trailblazer in Hong Kong's biomedical innovation technology landscape, was honored to be invited to the conference, alongside other pioneering technology innovation and entrepreneurial teams from the Hong Kong University of Science and Technology. Cognitact presence garnered widespread acclaim from a diverse audience from mainland China, including innovative pharmaceutical companies, research institutes, government leaders, renowned experts and scholars, accomplished entrepreneurs, and esteemed heads of investment firms.

At the conference, Cognitact Ltd. showcased its cutting-edge innovative technology: the breakthrough Alzheimer's disease blood biomarker detection technology, PlasmarkAD®. Dr. Joyce Ouyang, Managing Director of Cognitact Ltd., was invited to the "Roadshow Session for Unlisted Companies" session, where she shared Cognitact's journey as a classic case of commercializing an innovative technology from the Hong Kong University of Science and Technology (HKUST). She provided a detailed introduction to PlasmarkAD®, which simultaneously measures multiple protein biomarkers associated with Alzheimer's disease and employs a proprietary machine learning algorithm for analysis, enabling the early detection of Alzheimer's disease before the onset of symptoms. This highlighted the immense application potential of PlasmarkAD® in early Alzheimer's detection. The presentation attracted numerous mainland investment institutions, relevant companies, and research institutes, leading to in-depth one-on-one collaboration discussions with Cognitact's representatives.

Cognitact Limited is a biotechnology company focusing on the early detection of Alzheimer's disease. The company is committed to translating cutting-edge scientific research from one of the renowned local universities in Hong Kong into innovative early screening and diagnostic commercial tools, aiming to achieve early detection of neurodegenerative diseases through blood-based protein biomarker detection solutions. The successful hosting of the Biomed Innovation and Investment Conference provided an opportunity for Hong Kong's medical innovation companies to interact with mainland Chinese institutions and enterprises. It further allowed Cognitact to gain a deeper understanding and integrate into the ecosystem of collaboration and cooperation within the biomed industry in mainland China.

For more information about early detection of Alzheimer's disease, please contact Cognitact Limited.

Phone: 21161678

WhatsApp: 98051678

Official website: www.cognitact.com